Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

.:: Aurgalys Team ::.

Philippe Berthon, PhD

Philippe Berthon, General Partner

Chief Executive Officer – Evry-Paris France
ph.berthon@aurgalys.com

Philippe Berthon is Founder and Chief Executive Officer of Aurgalys, also board member Essonne Economy Agency. Previously, Dr Berthon was Chief Executive Officer of Vaxon-Biotech (2004-2008), a company developing cancer immunotherapeutic products at late clinical development stages.  Philippe founded UroGene in 1998, was CEO then President & CSO. UroGene was dedicated to urological diseases including cancer and incontinence, raised a total of €25M venture capital money, and was traded off to Groupe Pierre Fabre early 2005. Prior to these appointments, Dr Berthon was co-founder and CEO of CeRePP at Hospital Saint Louis, Paris, from 1995-1999; senior post-doctoral fellow at the Cancer Research Unit, University of York, UK, for 3 years; and research fellow at Paris VI University for 5 years. Dr Berthon co-authored more than 50 peer-reviewed international publications,  received his PhD in Reproduction Physiology at Paris VI University, and graduated from Challenge+ Business and Administration program, HEC School of Management, Jouy en Josas, France. Philippe Berthon is member of France Biotech, of Société Française des Analystes Financiers (SFAF) and Association des Analystes Conseil en Investissement Financier et Transmission d’Entreprises (ACIFTE).